XTL Biopharmaceuticals Ltd. (XTLB) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Market Cap | 243,978.16 |
| Enterprise Value | 436,978 |
| P/E Ratio | -0.83 |
| PEG Ratio | 0.01 |
| Price/Sales Ratio | 0 |
| Price/Book Ratio | -23.52 |
| Enterprise/Revenue | 0 |
| Enterprise/EBITDA | -5.13 |
| Fiscal Year | December 31, 2025 |
| Most Recent Quarter | December 31, 2025 |
| Profit Margin | 0 |
| Operating Margin | 0 |
| Return On Assets | -41.98 |
| Return On Equity | -2.69 |
| Revenue | 0 |
| Revenue/Share | 0 |
| Gross Profit | 0 |
| EBITDA | -752,000 |
| Net Income | -6.97M |
| Diluted EPS | -64 |
| Total Cash | 144,000 |
| Total Cash/Share | 0 |
| Total Debt | 269,000 |
| Total Debt/Equity | -1.06 |
| Current Ratio | 0.4 |
| Book Value Per Share | -0 |
| 52-Week Change | -55.37 |
| 52-Week High | 10.28 |
| 52-Week Low | 2.01 |
| Moving Average 50 Days | 2.67 |
| Moving Average 200 Days | 3.3 |
| Average Volume | 1.98M |
| Shares Outstanding | 2.37M |
| % Held by Institutions | 69.13 |
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0 |
| Payout Ratio | 0 |
| Last Split Factor | 1:4 |
| Last Split Date | March 25, 2026 |